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Proprotein convertase subtilisin/kexin type 9 (encoded by PCSK9) plays a well-known
role in the regulation of low-density lipoprotein (LDL) receptors, and an inhibitor of
this enzyme is a promising new therapeutic for hyperlipidemia. Recently, animal and
human studies also implicate PCSK9 genetic variation in the regulation of blood
pressure. The goal of this study was to examine if common and rare polymorphisms
in PCSK9 are associated with blood pressure in an African-American population at
high risk for cardiovascular disease. Using genomic data assayed on the Affymetrix
6.0 array (n = 1199) and the Illumina HumanExome Beadchip (n = 1966) from the
Hypertension Genetic Epidemiology Network (HyperGEN), we tested the association
of PCSK9 polymorphisms with blood pressure. We used linear mixed models and
the sequence kernel association test (SKAT) to assess the association of 31 common
and 19 rare variants with blood pressure. The models were adjusted for age, sex,
center, smoking status, principal components for ancestry and diabetes as fixed effects
and family as a random effect. The results showed a marginally significant effect of
two genome-wide association study (GWAS) single-nucleotide polymorphisms (SNPs)
(rs12048828: β = 1.8, P = 0.05 and rs9730100: β = 1.0, P = 0.05) with diastolic blood
pressure (DBP); however these results were not significant after correction for multiple
testing. Rare variants were cumulatively associated with DBP (P = 0.04), an effect that
was strengthened by restriction to non-synonymous or stop-gain SNPs (P = 0.02).
While gene-based results for DBP did not replicate (P = 0.36), we found an association
with SBP (P = 0.04) in the Reasons for Geographic And Racial Differences in Stroke
study (REGARDS). The findings here suggest rare variants in PCSK9 may influence
blood pressure among African Americans, laying the ground work for further validation
studies.
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Introduction
Hypertension is currently a major health problem in African
Americans (Kramer et al., 2004). Data from the National Health
and Nutrition Examination Survey (NHANES) in 2008 showed
that age-adjusted prevalence of hypertension was 40% in African
Americans vs. 30% in Caucasians (Egan et al., 2010). Over-
all, African Americans are more prone to hypertension-related
morbidity and mortality than Caucasians (Lackland, 2014). For
instance stroke risk is twice as high and risk for end-stage renal
disease is 4–5 times higher among African Americans (Go et al.,
2014). The reason for this disparity is not completely understood,
although differences in genetic background are hypothesized to
play a role (Allison et al., 1994; Kato, 2012). Because dyslipi-
demia is linked to hypertension, genetic variants associated with
lipid levels represent promising candidates for novel hyperten-
sion loci (Brown et al., 2000; Sesso et al., 2005; Halperin et al.,
2006; Nguyen et al., 2008; Maharjan et al., 2012; Yin et al., 2012).
Proprotein convertase subtilisin/kexin type 9 (encoded by
the PCSK9 gene) contributes to low-density lipoprotein (LDL)
cholesterol levels by reducing cell surface expression of LDL
receptors. Mutations in PCSK9 can cause hypercholesterolemia
(gain of function) and hypocholesterolemia (loss of function),
which has made it an attractive therapeutic target for the treat-
ment of dyslipidemia (Horton et al., 2007; Abifadel et al., 2009).
Recently, research in an animal model suggested a role for
PCSK9 in the regulation of blood pressure (Sharotri et al., 2012),
showing that the PCSK9 gene product decreases trafficking of
the epithelial sodium channel (ENaC) protein to the cell sur-
face in Xenopus oocytes by enhancing proteasomal degradation.
ENaC forms a pathway for sodium to enter epithelial cells at
the apical membrane, thus regulating sodium absorption in the
kidney and contributing to blood pressure regulation. There-
fore, PCSK9 activity could affect blood pressure by modulating
sodium absorption. Becausemost previous studies of PCSK9 have
focused on cholesterol metabolism, the role of PCSK9 in blood
pressure is a novel area of investigation. To address this gap, we
examined the association of common and rare variants in PCSK9
and blood pressure in a population of African Americans at high
risk for cardiovascular disease.
Methods
Study Population
We used clinical and genetic data collected from African Amer-
icans participating in the Hypertension Genetic Epidemiology
Network (HyperGEN) study. HyperGEN was designed to study
genes promoting hypertension as part of the Family Blood
Pressure Program funded by the National Heart, Lung and
Blood Institute. African-American participants were recruited in
Forsyth County, NC and Birmingham, AL from siblings who
were diagnosed with hypertension before age 60 years and had
a least one additional hypertensive sibling who agreed to partici-
pate. In the second phase of the study, the offspring of the original
sib-pairs were recruited. The HyperGEN study was approved by
Institutional Review Boards of the collaborating institutions. All
participants gave written informed consent.
Participants with type 1 diabetes or advanced renal disease
(defined as serum creatinine level > 2mg/dL) were excluded
from the parent HyperGEN study since these two conditions can
cause secondary hypertension and the focus of HyperGENwas to
identify novel essential hypertension loci. Patients taking lipid-
lowering agents or missing lipid-lowering treatment data were
excluded from the current analysis (n = 59 from the common
variant analysis and 145 in the rare variant analysis).
Clinical Variables
Six consecutive BP measurements were made during the study
visit, three on the left and three on the right arm. The participants
rested for 5min before measurement and for 30 s between mea-
surements (Knox et al., 2010). An average sitting systolic blood
pressure (SBP) and diastolic blood pressure (DBP) was calcu-
lated based on the second and third measurements in the second
arm. Blood pressure measurements were obtained using auto-
mated Dinamap devices (model 1846 SX/P, Critikon, Tampa, FL)
to promote comparable measurements among HyperGEN field
centers. Hypertension was defined as average SBP ≥ 140mm
Hg or average DBP ≥ 90mm Hg, or using at least one class
of antihypertensive medication. Participants were categorized as
treated if they were taking at least one antihypertensive medica-
tion according to the Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7) classifications (Chobanian et al.,
2003). Participants were categorized as having diabetes if they
were on anti-diabetic medications or insulin treatment, or had
fasting glucose ≥126mg/dl.
More details regarding study design and methodology of the
HyperGEN study are available in previous publications (Williams
et al., 2000).
Genotyping
Common Variants
DNA extraction and purification from stored blood were per-
formed using commercial Puregene reagents (Gentra System,
Inc., Minneapolis, MN) as previously described (Williams et al.,
2000). Genome-wide association study (GWAS) genotyping was
performed using the Affymetrix Genome-Wide Human SNP 6.0
Array following the Affymetrix defined protocol (Arnett et al.,
2011). Using a subset of 1258 subjects, approximately 3.01million
HapMap SNPs were imputed using MACH v. 1.0 with Human
Genome Build 36 as the reference. Overlapping SNP genotypes
were 99.5% concordant in the imputed dataset as compared to the
genotype data set. SNPs whichwere not inHapMap (n = 94.337),
monomorphic (n = 14.363), R2 < 0.3, minor allele frequency
(MAF) < 1%, or Hardy-Weinberg equilibrium (HWE) P ≤ 10−6
(n = 150.096) were removed from the imputed dataset. The
overall Mendelian error rate was 0.045%. A total of 50 common
variants in PCSK9 were obtained from the imputed GWAS data
in 1199 samples. Using Haploview (Barrett et al., 2005) with r2
threshold at 0.8 to examine linkage disequilibrium between the
50 common SNPs (Supplementary Material), we chose 31 inde-
pendent tag SNPs in PCSK9 for our analysis. We additionally
considered the associations of 3 SNPs located near PCSK9 that
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were reported in prior GWAS of lipid traits [rs11206510 (Schun-
kert et al., 2011), rs2479409 (Willer et al., 2013), and rs2495478
(Turnbull et al., 2012)] with both SBP and DBP.
Rare Variants
Study samples were processed on the HumanExome BeadChip
v1.0 (Illumina, Inc., San Diego, CA) using manufacturer proto-
cols for a total of 2111 samples. The total number of SNPs assayed
was 242,901. Monomorphic SNPs (n = 105.723), SNPs with
missing rate >5% (n = 36), and SNPs with Hardy-Weinberg
equilibrium P < 10−6 (n = 175) were removed. The Mendelian
error rate was 0.002%. A total of 19 rare variants (MAF < 0.01)
in PCSK9 were included in this analysis from 1966 samples.
There were 1131 samples that had both common and rare vari-
ant data available for PCSK9 from GWAS and exome chip assays,
respectively.
Statistical Methods
To reduce bias and improve statistical power, the effect of anti-
hypertensive treatment was controlled by adding 15mm Hg to
observed SBP and 10mm Hg to DBP for those who reported
taking medications (Tobin et al., 2005). To control for popu-
lation substructure 10 principal components were generated in
Eigenstrat (Price et al., 2006).
For common PCSK9 variants, we used linear mixed models
adjusted for age, sex, center, smoking status, principal compo-
nents, diabetes (fixed effects), and family (random effect) to eval-
uate main genetic effects. For rare variants, we used the sequence
kernel association test (SKAT) (Wu et al., 2011) adjusting for the
same covariates. We also examined the joint effect of common
and rare variants in PCSK9 with blood pressure among the subset
with both GWAS and exome chip data (n = 1131) using SKAT.
Common variants that achieved nominal statistical significance
(P < 0.05) in the mixed models were selected to test the joint
effect.
A P-value of 0.05 was considered as suggestive evidence for an
association. A Bonferroni correction was used to correct for mul-
tiple tests of common variants, where the type 1 error rate was
equal to 0.05/31 = 0.0016. R version 3.0.2 was used for SKAT and
SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) was used for
all other analyses.
Replication
Results from HyperGEN reaching at least marginal significance
(P ≤ 0.05) were tested in The REasons for Geographic And
Racial Differences in Stroke (REGARDS) Study. REGARDS is a
national, population-based, longitudinal study of incident stroke
and associated risk factors among 30,239 African-American and
European-American adults aged ≥ 45 years. Participants were
randomly sampled and contacted by mail, then telephone, and
enrolled between 2003 and 2007. A total of 7700 randomly
selected African Americans were recently genotyped with the
same Illumina exome chip as HyperGEN. Similar QC as in
HyperGEN was carried out (Howard et al., 2005). There was a
total of 1502 participants with GWAS data and 4960 participants
with exome chip data after we excluded those with missing
information on blood pressure or antihypertensive treatment
and those on lipid-lowering drugs. We used similar statistical
methodology and adjustment for covariates including ancestry
to examine the association of selected variants with blood pres-
sure in REGARDS. The REGARDS study was approved by Insti-
tutional Review Boards of the collaborating institutions and all
participants gave written informed consent.
Results
Table 1 shows the baseline characteristics of HyperGEN par-
ticipants with PCSK9 variant data available from GWAS, the
exome chip, and both assays. The majority of participants were
middle-aged and female, as well as obese (BMI ≥ 30 kg/m2) and
TABLE 1 | Baseline characteristics for African-American participants with
exome chip data, GWAS data, and both data sets.
Exome chip GWAS Both
(N = 1966) (N = 1199) (N = 1131)
N % N % N %
AGE, YEARS
<30 226 11.4 178 14.9 161 14.2
30–60 1431 72.2 849 70.8 802 70.9
60+ 326 16.4 172 14.3 168 14.9
SEX
Male 729 36.8 393 32.8 368 32.5
Female 1254 63.2 806 67.2 763 67.5
CENTER
Forsyth County, NC 495 24.9 247 20.6 223 19.7
Birmingham, AL 1488 75.1 952 79.4 908 80.3
SMOKING
Never 979 50.2 618 52.0 570 50.8
Ever 971 49.8 571 48.0 552 49.2
CURRENT SMOKING
No 1392 71.4 862 72.5 808 72.0
Yes 558 28.6 327 27.5 314 28.0
DBP, mm Hg
<90 1791 90.3 1086 90.6 1022 90.4
≥90 192 9.7 113 9.4 109 9.6
SBP, mm Hg
<140 1434 72.3 863 72.0 815 72.1
≥140 549 27.7 336 28.0 316 27.9
HYPERTENSION
No 822 41.4 470 39.2 433 38.3
Yes 1161 58.6 729 60.8 698 61.7
DIABETES
No 1648 83.1 1005 83.8 945 83.6
Yes 335 16.9 194 16.2 186 16.4
BMI, kg.m2
<25 124 6.3 98 8.2 90 8.0
25–29.9 102 5.1 80 6.7 71 6.3
30+ 1757 88.6 1021 85.1 970 85.7
BMI, body mass index; DBP, diastolic blood pressure; GWAS, Genome-wide association
study; SBP, systolic blood pressure.
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TABLE 2 | Main effects of 31 common variants in PCSK9 on blood
pressure in GWAS*.
# Common Location A1+/ MAF HWE β SE P-value
SNPs chromosome 1 A2 P-value
1 rs1603717_A 55733832 A/G 0.3 0.3
DBP 0.6 0.5 0.3
SBP −0.3 0.98 0.8
2 rs12048828_C 55735734 C/T 0.08 0.6
DBP 1.8 0.93 0.05
SBP 0.5 1.7 0.8
3 rs6698904_T 55737077 T/C 0.03 0.6
DBP −0.8 1.5 0.6
SBP −1.4 2.8 0.6
4 rs6588553_C 55737455 C/T 0.2 0.1
DBP −0.6 0.6 0.3
SBP −1.5 1.1 0.2
5 rs10443235_C 55738353 C/T 0.4 0.6
DBP 0.2 0.5 0.7
SBP 0.5 0.95 0.6
6 rs12086676_C 55738663 C/T 0.4 0.5
DBP −0.6 0.5 0.3
SBP 0.06 0.9 0.95
7 rs12076372_A 55738727 A/C 0.1 1
DBP −0.5 0.7 0.5
SBP −1.7 1.3 0.2
8 rs6657064_G 55738918 G/C 0.3 0.7
DBP −0.4 0.5 0.4
SBP −0.9 0.97 0.4
9 rs2088487_T 55739925 T/C 0.3 0.2
DBP −0.5 0.5 0.3
SBP −0.5 0.95 0.6
10 rs17101343_C 55741315 T/C 0.06 0.2
DBP 0.02 1.05 0.98
SBP −2.0 1.9 0.3
11 rs6588555_A 55741377 A/G 0.1 0.06
DBP 0.1 0.8 0.9
SBP 0.02 1.4 0.98
12 rs12035319_T 55742746 T/C 0.02 1
DBP 3.4 1.9 0.07
SBP 1.9 3.4 0.6
13 rs2047418_G 55743099 G/C 0.2 0.3
DBP −0.6 0.6 0.3
SBP −0.6 1.0 0.5
14 rs1874776_C 55743519 T/C 0.3 0.2
DBP −0.8 0.5 0.1
SBP −0.7 0.96 0.5
15 rs2047420_T 55744429 T/G 0.4 0.5
DBP −0.2 0.5 0.6
SBP −1.6 0.95 0.1
16 rs4926675_A 55744950 A/G 0.2 0.5
DBP 0.7 0.7 0.3
SBP −0.2 1.1 0.9
17 rs11206551_A 55744966 G/A 0.1 0.1
DBP −0.2 0.8 0.8
SBP 0.7 1.5 0.7
(Continued)
TABLE 2 | Continued
# Common Location A1+/ MAF HWE β SE P-value
SNPs chromosome 1 A2 P-value
18 rs12077573_G 55746146 C/G 0.1 0.1
DBP −1.1 0.8 0.1
SBP −2.0 1.4 0.1
19 rs12071742_A 55747825 A/G 0.4 0.08
DBP 0.5 0.5 0.3
SBP 1.6 0.95 0.08
20 rs17405810_C 55748043 C/G 0.08 0.04
DBP −0.05 0.9 0.95
SBP 0.4 1.7 0.8
21 rs9787035_C 55748166 C/A 0.01 0.3
DBP −1.0 1.0 0.6
SBP 2.2 3.6 0.5
22 rs17111836_T 55748970 T/C 0.08 0.7
DBP 0.9 0.9 0.3
SBP 1.6 1.7 0.3
23 rs4927218_A 55749649 A/G 0.05 0.6
DBP −1.0 1.2 0.4
SBP 1.5 2.1 0.5
24 rs9730100_C 55750600 C/A 0.4 0.4
DBP 1.0 0.5 0.05
SBP 1.3 0.9 0.2
25 rs4927219_A 55751821 A/G 0.3 0.3
DBP 0.9 0.6 0.1
SBP 1.1 1.0 0.3
26 rs17111859_T 55752440 T/C 0.2 0.5
DBP −0.1 0.6 0.9
SBP 1.3 1.1 0.2
27 rs17111863_C 55752896 C/T 0.09 1
DBP 0.8 0.9 0.3
SBP 2.3 1.6 0.1
28 rs11809596_A 55753233 G/A 0.5 0.2
DBP 0.2 0.5 0.7
SBP 0.9 0.9 0.3
29 rs17111872_C 55755376 C/G 0.1 0.6
DBP 0.8 0.7 0.3
SBP 2.0 1.3 0.1
30 rs17111875_C 55757023 C/A 0.03 1
DBP 1.4 1.4 0.3
SBP 3.2 2.5 0.2
31 rs10888912_A 55757807 A/G 0.3 0.5
DBP 0.4 0.6 0.4
SBP −0.3 1.0 0.8
*Model adjusted for age, sex, center, smoking status, diabetes, and family random effect.
*A1, minor allele; β, regression coefficient; DBP, diastolic blood pressure; GWAS, genome-
wide association study; HWE, Hardy-Weinberg Equilibrium; MAF, minor allele frequency;
SBP, systolic blood pressure; SE, standard error.
Bold values signifies significant results at P ≤ 0.05.
hypertensive. Diabetes prevalence did not exceed 17% in any sub-
set. The REGARDS population was also mostly female (64%),
but was, on average, older (mean age 63.9 ± 9) with a higher
prevalence of diabetes (24.5%).
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All SNPs were in HWE except for rs17405810 (HWE P =
0.04).Table 2 shows the association of the 31 common SNPs with
blood pressure. The SNPs rs12048828 and rs9730100 were both
marginally associated with DBP (both P = 0.05). There were
no significant associations observed with SBP. The two GWAS
SNPs did not show significant association with DBP (P = 0.44 for
rs4927219 and 0.89 for rs12048828) or SBP (P = 0.19 and 0.42,
respectively) in the REGARDS population (rs4927219 was used
as a proxy for rs9730100) (Ward and Kellis, 2012). Our look-up
of 3 known lipid loci near PCSK9 from prior GWAS showed no
significant association with DBP or SBP [rs11206510 (P = 0.3 for
DBP and 0.8 for SBP), rs2479409 (P = 0.1 for DBP and 0.4 for
SBP), and rs2495478 (P = 0.7 for DBP and 0.6 for SBP)]. Table 3
annotates 19 rare variants in PCSK9 (MAF ≤ 0.01) included in
this study. Overall, we observed a higher median SBP and DBP
for carriers of non-synonymous SNPs (Table 3) compared to
non-carriers (median SBP and DBP for non-carriers is 127mm
Hg and 73mm Hg, respectively). Association analysis demon-
strated a significant cumulative effect of rare variants with DBP
(P = 0.04) but not with SBP (P = 0.14) in HyperGEN. We sepa-
rately tested the association of 16 non-synonymous or stop-gain
SNPs and 3 synonymous SNPs with DBP where there was a sig-
nificant cumulative effect of non-synonymous or stop-gain SNPs
(P = 0.02) but not synonymous SNPs (P = 0.73). The joint effect
of rs12048828, rs9730100, and 19 rare variants was not statisti-
cally significantly associated with either DBP (P = 0.07) or SBP
(P = 0.53). However, the joint effect of the 2 GWAS SNPs and 16
non-synonymous SNPs was significant for DBP (P = 0.03) but
not for SBP (P = 0.41).
TABLE 3 | PCSK9 rare variants in the exome chip data.
No SNP rs# Location on Nucleotide Protein Annotation MAF Number of HWE SBP DBP
chromosome 1 position position carriers P-value median median
1 exm62588 rs11591147 55505647 c.137 G>T p.R46L Non-synonymous 0.002 9 1 137 89
2 exm62591 rs145886902 55505679 c.169 G>A p.E57K Non-synonymous 0.002 8 1 133 66
3 exm62606 rs67608943 55512222 c.426 C>G p.Y142X Stop-gain 0.004 15 1 116 75
4 exm62607 Not available 55512267 c.471 C>A p.N157K Non-synonymous 0.0002 1 1 165 97
5 exm2263347 rs149489325 55518371 c.706 G>A p.G236S Non-synonymous 0.002 3 1 135 81
6 exm62636 rs72646508 55518422 c.757 C>T p.L253F Non-synonymous 0.003 14 1 128 75
7 exm62652 Not available 55523076 c.1069C>T p.R357C Non-synonymous 0.0002 1 1 122 75
8 exm62659 rs146471967 55523178 c.1171 C>A p.H391N Non-synonymous 0.002 10 1 138 82
9 exm62666 rs143275858 55523779 c.1251 C>A p.H417Q Non-synonymous 0.002 7 1 132 78
10 exm62667 rs28362261 55523802 c.1274 A>G p.N425S Non-synonymous 0.01 72 0.139 135 79
11 exm62678 rs141502002 55524222 c.1405 C>T p.R469W Non-synonymous 0.01 40 0.211 129 76
12 exm1834776 rs141995194 55524262 c.1445 A>G p.E482G Non-synonymous 0.002 6 1 130 80
13 exm62699 rs28362270 55525313 c.1658 A>G p.H553R Non-synonymous 0.01 55 0.3558 134 76
14 exm62700 rs140364657 55525315 c.1851 C>G p.Q554E Non-synonymous 0.001 6 1 135 78
15 exm62708 rs28362277 55527222 c.1856 A>C p.Q619P Non-synonymous 0.01 60 1 146 84
16 exm62720 rs28362286 55529215 c.2037 C>A p.C679X Stop-gain 0.009 34 1 129 76
17 exm62616 rs148612296 55517952 c.525 C>T p.D175D Synonymous 0.009 34 1 136 77
18 exm2252207 rs28385710 55518418 c.753C>T p.R251R Synonymous 0.0002 1 1 207 105
19 exm2252208 rs140364657 55527217 c. 1851 C>T p.A617A Synonymous 0.006 20 1 135 79
DBP, diastolic blood pressure; HWE, Hardy-Weinberg Equilibrium; MAF, minor allele frequency; SBP, systolic blood pressure.
In REGARDS data, 18 of 19 PCSK9 SNPs from exome chip
data (SNP “exm62667” did not pass QC in the REGARDS
dataset) were available for our analysis. PCSK9 rare variants had
a cumulative significant association with SBP (P = 0.04) but not
with DBP (P = 0.36). The results did not change when restricted
to 15 non-synonymous SNPs (P = 0.04 for SBP and P = 0.40 for
DBP).
Discussion
Using existing exome chip and GWAS data from HyperGEN,
we tested the association of PCSK9 polymorphisms with blood
pressure. We found a marginal effect of two GWAS SNPs
(rs12048828 and rs9730100) and a significant cumulative effect
of all PCSK9 rare variants, driven by non-synonymous SNPs,
on DBP. Though our results for the two GWAS SNPs and for
DBP did not replicate, we found a cumulative association with
SBP in REGARDS, suggesting that rare variants in PCSK9 may
be important for blood pressure regulation. Overall, the median
blood pressure was higher by rare-variant status in our study
suggesting that these variants may downregulate function (i.e.,
less degradation of ENaC); however we cannot draw conclusions
based on our research and future studies are required to under-
stand the functional impact of these variants.
PCSK9 is located on chromosome 1p32.3. It has 12 exons
and encodes a 692 amino acid glycoprotein belonging to the
family of protein convertases (Benjannet et al., 2004). More
than 53 non-synonymous variants and 17 synonymous variants
associated with cholesterol metabolism have been identified (Abi-
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fadel et al., 2009). Additionally, the rs11206510 (Schunkert et al.,
2011), rs2479409 (Willer et al., 2013), and rs2495478 (Turnbull
et al., 2012) variants have been highlighted by previous GWAS
of lipid traits. Despite the plethora of studies on PCSK9 muta-
tions in cholesterol metabolism (Abifadel et al., 2003), its role in
the etiology of hypertension remains poorly understood. A recent
animal study (Sharotri et al., 2012) showed that PCSK9 could alter
blood pressure by modulating sodium absorption through ENaC.
In that study PCSK9 degraded ENaC during trafficking to the cell
membrane, an effect linked to decreased blood pressure. PCSK9
degradation of LDL-R at the cell membrane surface increases
cholesterol. However, the mechanism of action of PCSK9 on
degration of ENaC and LDL-R (during trafficking to the cell
membrane vs. at the cell membrane, respectively) is different,
and teasing out how these polymorphisms affect the function
of PCSK9 in relation to blood cholesterol and blood pressure
was beyond the scope of this study. Recent evidence from a
mouse model suggests that knocking out the PCSK9 gene does
not change BP or sodium balance in mice (Berger et al., 2015).
Our findings are clearly discrepant in comparison to that report,
which may be due to insufficient homology between humans and
mice, statistical power, or chance.
In addition to animal studies, a recent report examined the
association of PCSK9 and eight other lipid-related gene poly-
morphisms with blood pressure in a Chinese population strati-
fied by gender (Yin et al., 2012). They tested only one variant of
PCSK9, rs505151 (E670G), and reported a correlation with DBP
in both male and female hypertensive groups. However, rs505151
did not have significant effect on DBP in the HyperGEN sample
(P = 0.37). To our knowledge, our study is the first to investi-
gate the association of multiple common and rare PCSK9 variants
with blood pressure. Interestingly in our study the association of
PCSK9was observed only withDBP in theHyperGEN cohort and
only with systolic blood pressure in the REGARDS cohort. This
discrepancy could be due to differences between the REGARDS
andHyperGEN populations. REGARDS participants are on aver-
age older than HyperGEN participants 64± 9 vs. 46 ± 13. Mean
SBP (131 ± 17 in REGARDS vs. 129 ± 22 in HyperGEN) and
DBP (79 ± 10 in REGARDS and 74 ± 12 in HyperGEN) are
slightly lower in HyperGEN and there is a higher prevalence of
antihypertensive treatment in REGARDS (68% vs. 57%). Impor-
tantly, hypertension at younger ages is characterized by increased
DBP. As the arteries age and become more atherosclerotic, SBP
becomes the dominant hypertension trait (Chrysant, 2013). If
PCSK9 is truly associated with hypertension, then it is reason-
able to speculate it would associate with DBP at younger ages and
SBP at older ages.
The strength of our study is the inclusion of African Amer-
icans, a historically under-represented population in genomic
studies. Moreover, the majority of our population is also obese
and, thus, at high risk for cardiovascular disease. Also, our study
is the first to examine the association of multiple variants in
PCSK9 with blood pressure. Our findings must also be inter-
preted in context of some limitations. First, our study does not
capture all common and rare variants in PCSK9. Future sequenc-
ing studies of African-American populations are necessary to
fully cover the gene. Second, as PCSK9 variants are unequally
distributed in different populations (Abifadel et al., 2009), our
findings might not generalize to other ethnic groups.
On balance, our results support the emerging hypothesis that
PCSK9 rare variantsmay have an involvement in the regulation of
blood pressure. Upon further validation, our results may provide
additional evidence of the pleiotropic function of PCSK9. Future
studies should capitalize on sequencing data to further support
or refute these hypotheses.
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